Lawsuits filed in opposition to the White House's drug pricing negotiation program are beginning to mount, but legal experts agree that the plaintiffs’ arguments probably won’t hold up during a court battle. However, these lawsuits still could delay when the government's ability to negotiate price goes into effect.
America’s Health Insurance Plans' new campaign aims to show how health insurers are working to create savings for Americans while also targeting Big Pharma (or more specifically drug manufacturers) for increasing drug costs. The ads will be distributed on TV, social media and streaming services.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Pharma companies often take the blame for high prescription costs. But a new, industry-sponsored survey shifts attention to insurance industry practices.
Not all drugs will be subject to price negotiation under the revised legislation. But the agreement sets up a framework enabling Medicare to negotiate the prices of medicines that have been on the market for a long time, and also caps the monthly price of insulin, which has been a flashpoint of drug price debate.
Recent efforts to improve transparency haven't made much of a difference, one author noted. But earlier reforms made a dent the "most egregious" practices.
U.S. District Judge Amit Mehta in Washington, D.C. ruled in favor of pharma companies challenging the rule in court because of what he said was a lack of statutory authority from the HHS to govern drug marketing.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
At an event during the annual American Diabetes Association Scientific Sessions in San Francisco, representatives from PBM, health plan, drug manufacturing and patient advocacy groups came together to discuss the causes of increasing insulin prices and potential solutions to the problem.
The changes will take place 60 days after the rule is published in the Federal Register. Industry trade group PhRMA have opposed the rule, saying it will lead to consumer confusion and sticker shock that could discourage medication use.
The Washington Post reported Tuesday that Gottlieb, who was appointed FDA commissioner in May 2017, is leaving the agency. In January, he had denied rumors that he would be departing.
Accusations of "freeloading" seen as misleading, and the proposed changes - which would start in 2020 - wouldn't help patients covered under Part D or commercial plans.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
A legal expert compared mandatory prices in ads to food labeling, but another expert said mandating them risks scaring patients out of taking life-saving medicines.
The industry's main lobbying group, PhRMA, updated its direct-to-consumer ad guidelines to include pricing information, but HHS secretary says voluntary action is insufficient.
A KHN analysis found that 47 of the drugs cost Medicare and Medicaid almost $12 billion in 2016. The spending totals don’t include rebates, which drugmakers return to the government after paying for the drugs upfront but are not public.
With federal officials seemingly unwilling or unable to come up with legislation to control skyrocketing drug prices, that task is increasingly moving to the states. But so is pharma muscle and money opposing the measures.
Pharmaceutical Research and Manufacturers of America’s state and federal lobbying spending rose by more than two-thirds from the previous year, to $57 million.